| Literature DB >> 22877315 |
Jordi L Tremoleda1, Angela Kerton, Willy Gsell.
Abstract
The implementation of imaging technologies has dramatically increased the efficiency of preclinical studies, enabling a powerful, non-invasive and clinically translatable way for monitoring disease progression in real time and testing new therapies. The ability to image live animals is one of the most important advantages of these technologies. However, this also represents an important challenge as, in contrast to human studies, imaging of animals generally requires anaesthesia to restrain the animals and their gross motion. Anaesthetic agents have a profound effect on the physiology of the animal and may thereby confound the image data acquired. It is therefore necessary to select the appropriate anaesthetic regime and to implement suitable systems for monitoring anaesthetised animals during image acquisition. In addition, repeated anaesthesia required for longitudinal studies, the exposure of ionising radiations and the use of contrast agents and/or imaging biomarkers may also have consequences on the physiology of the animal and its response to anaesthesia, which need to be considered while monitoring the animals during imaging studies. We will review the anaesthesia protocols and monitoring systems commonly used during imaging of laboratory rodents. A variety of imaging modalities are used for imaging rodents, including magnetic resonance imaging, computed tomography, positron emission tomography, single photon emission computed tomography, high frequency ultrasound and optical imaging techniques such as bioluminescence and fluorescence imaging. While all these modalities are implemented for non-invasive in vivo imaging, there are certain differences in terms of animal handling and preparation, how the monitoring systems are implemented and, importantly, how the imaging procedures themselves can affect mammalian physiology. The most important and critical adverse effects of anaesthetic agents are depression of respiration, cardiovascular system disruption and thermoregulation. When anaesthetising rodents, one must carefully consider if these adverse effects occur at the therapeutic dose required for anaesthesia, if they are likely to affect the image acquisitions and, importantly, if they compromise the well-being of the animals. We will review how these challenges can be successfully addressed through an appropriate understanding of anaesthetic protocols and the implementation of adequate physiological monitoring systems.Entities:
Year: 2012 PMID: 22877315 PMCID: PMC3467189 DOI: 10.1186/2191-219X-2-44
Source DB: PubMed Journal: EJNMMI Res Impact factor: 3.138
Figure 1Example of PET/CT acquisitions showing fasting effects on biodistribution of 18 F-FDG-PET tracer in C57BL/6 mice. (A, B) Maximum intensity projection, and (A′, B′) two-dimensional coronal view. The fasted animals displayed a more targeted and selective uptake of the glucose analogue tracer throughout the body, avoiding the general uptake throughout the whole digestive system due to food ingestion.
Properties of main anaesthetic agents used in preclinical research: halothane and isoflurane
| Halothane | Potent anaesthetic | Highly metabolised (hepatotoxic) | Induction 3% to 4% Maintenance 1% to 2% (rats and mice) |
| | High therapeutic index | Cardiovascular depressant | |
| | Rapid induction and recovery (1 to 3 min) | Moderate hypotension: reduction in cardiac output and peripheral vasodilatation) | |
| | Adequate muscle relaxation | Respiratory depressant | |
| | Non-irritant, non-flammable nor explosive | Halothane sensitises the heart to catecholamines (sympathetic stimulation) | |
| | Easy to vaporise | | |
| Isoflurane | Similar physical properties to halothane | Decreases arterial blood pressure (vasodilatation) | Induction 3% to 4% (rats and mice) Maintenance: 1.5% to 2% (mice)1.5% to 2.5% (rats) |
| | Rapid induction and recovery | More expensive than halothane | |
| | Low toxicity and metabolic activity: highly safe | Strong smell: aversive | |
| | Suitable for high frequency and long-term anaesthesia | More potent respiratory depressant than halothane | |
| | Minimal cardiovascular depression | | |
| | Moderate respiratory depression | | |
| Good muscle relaxation |
Summary of the properties of injectable anaesthetics
| Fentanyl/fluanisone (Hypnorm™)-based combination | Good analgesic effect | Cardiovascular and respiratory depression | 10 ml/kg (mouse), 2.7 ml/kg (rat) i.p. mixture Hypnorm™/Hypnovel™ (midazolam)/water mixture (1:1:2 volume) (120 to 140 min sleep time)Hypnorm™ top-up 0.3 ml/kg (mouse), 0.1ml/kg (rat) i.p. (30 to 40 min sleep time) |
| | Sedative | Poor muscle relaxation alone | |
| | Possible to top-up for long-term anaesthesia | Risk of enterohepatic recirculation: relapse | |
| | Reversal of sedative effect with buprenorphine to speeds up recovery time | Prolonged recovery time | |
| | | Hypersensitivity to noise | |
| Ketamine-based combination | Analgesic effects | Muscle rigidity +++ unless combined with other agents. | Ketamine + medetomidine 75 mg/kg + 0.5 to 1 mg/kg i.p.(Ketamine + xylazine 75 to 100 mg/kg)/(10mg/kg i.p.)(60 to 120 min sleep time ) (mouse and rats)Atipamezole 1mg/kg i.p. |
| | Light sedation | Increases intracranial pressure. | |
| | Wide safety margin | Recovery often involved with ataxia and hyper responsiveness. | |
| | | Can increase blood pressure | |
| Alfaxalone (Alfaxan) | Minimal respiratory or CVS depression | Administration route i.v. (rodents, cats) or i.m. (primates) | 15 to 20mg/kg (mouse), 10 to 12mg/kg (rat) i.v.(10 to 15 min sleep time after bolus)0.25 to 0.75 mg/kg/min i.v. infusion (long term) |
| | Rapidly metabolised, repeated doses do not accumulate. | | |
| | Suitable for long-term anaesthesia in rodents | | |
| Propofol (Rapinovet®, Diprivan®) | Rapidly metabolised, continuous infusion possible for long-term anaesthesia. | i.v. use only | 26 mg/kg (mouse), 10 to 12mg/kg (rat) i.v.(10 to 15 min sleep time after bolus)2 to 2.5 mg/kg/min i.v. infusion (long-term, mouse) 0.5 to 1 mg/kg/min i.v. infusion (long-term, rat) |
| | | No analgesic properties | |
| | Rapid recovery | Severe respiratory depression | |
| | Can be used in animals with hepatic or renal impairment. | Apnoea can occur after i.v. bolus | |
| Barbiturates products | Sedative effect | No analgesic properties | Pentobarbitone, 40 to 50mg/kg i.p. (mouse) (120 to 180 min sleep) |
| | Good hypnotic effect | Severe respiratory depression and hypotensive | |
| | Reasonable muscle relaxation | Easy to overdose | Thiopentone, 30 mg/kg i.v. 15 min sleep (rat) |
| | | Metabolites accumulate with time | |
| | | Caustic substances (thiopentone only i.v. route) | |
| Chloral hydrate | Sedative effect | No analgesic properties | 300 to 400 mg/kg i.p. (1 to 2 h sleep time) (mouse and rats) |
| | Good hypnotic effect | Paralytic ileus noted in rats | |
| | Minimal CVS and respiratory depression | Terminal/non-recovery work only | |
| Sedative effect | No analgesic properties | 50 to 60 mg/kg i.p. (rats), 120 mg/kg i.p. (mouse)(8 to 12 h for non-recovery only)50 mg/kg i.v. bolus followed by 25 to 40 mg/kg/h (rats) | |
| | Good hypnotic effect | i.v. use only | |
| | Suitable for long-term anaesthesia | Slow induction and recovery associated with involuntary excitement | |
| | Minimal CVS and respiratory depression | Terminal/non-recovery work only | |
| Urethane | Suitable for long-term anaesthesia. | Carcinogenic: only allowed to be used with special justification | 0.8 to 1.3 g/kg i.p. (mouse and rats)Duration of action 8 to 10 h (non-recovery only) |
| | Minimal CVS and respiratory depression | Terminal/non-recovery work only | |
| | | | |
| Avertin® (tribromoethanol) | Wide safety margin | Local irritation/peritonitis | 0.015 ml/g body wt of 2.5% i.p. |
| | Good muscle relaxation | Handling and storage safety issues | 30 min; supplemental doses of anaesthesia: minimum of 1/2 of the initial dose up to 1 ml maximum volume per animal |
| Rapid induction and recovery | Toxic effects |
Figure 2Image displaying some of examples of respiratory monitoring equipment. (a) Respiratory sensor (VioHealthcare, Uckfield, UK); (b) Capnographs used for rodents: (i) type 340 Capnograph system (Harvard Apparatus, Holliston, MA, USA) with specifications for working with mouse or rats; (ii) MRI adaptable system: V9004 Capnography/Pulse oximeter (Harvard Apparatus); and (iii) PhysioSuite (Kent Scientific Corporation, Torrington, CT, USA) CapnoScan to measure the end tidal CO2.
Figure 3Changes in arterial Osaturation and POand examples of whole pattern activation. (a) Changes in arterial O2 saturation and PO2 under different O2 gas concentrations during anaesthesia. These parameters can affect the BOLD response during MRI; therefore, it is important to monitor blood gas levels during such functional MRI studies [54]. (bc) Example of whole pattern activation in a rat brain erratically induced by too deep isoflurane anaesthesia. Such a ‘bad’ activation pattern in the whole brain (c) would mask any specific activation due to a pharmacological and/or sensorial stimulus, and in this case, the time course shows (b) a general decline in signal, and no effect of the challenge is visible.
Figure 4ECG electrodes systems. (a) System BioVet™ (©m2m Imaging Corp, Newark, USA): the carbon fibre electrodes are applied directly in contact with the cleaned and shaved chest skin and applied with gel electrode so that a minimal impedance electrical connection is made with the electrode. (b) Model 1025 small animal monitoring and gating system (Small Animal Instruments, Inc., Stony Brook, NY, USA): the ECG system used for the MRI scanners uses sub-dermal needle electrodes, pads or surface electrodes. The placement of the electrodes is typically in or on the right forepaw and the left hind pore, or electrodes are placed in the forepaw as long as it is across the heart plane. All the wire bundles within the scanner should be taped to eliminate unwanted movement from the gradient vibration and/or air flow. (c) Schematic representation of the fMRI setting: all the equipment needs to be non-ferromagnetic, and it is connected to a module system which allows gated acquisition of images, avoiding interferences from motion due to breathing and /or heart beating. Body temperature is also regulated through a heating module (small rodent heater system; Small Animal Instruments, Inc.) to monitor and control the animal temperature during imaging. The system software continuously processes the temperature measurements and sends an optical control signal to the heater control module. The rate of change of temperature is monitored, and heater control is adjusted to regulate temperature changes. Mouse temperature variations of less than ±0.1°C can typically be obtained during magnetic resonance (MR) examination.
Figure 5Images displaying the clip sensors used by the pulse oximeter systems. (a) In the base of the mouse or (b) in the centre of the foot in rat. The MouseOx® murine pulse oximeter system from Starr Life Sciences® Corp. (Oakmont, PA, USA) provides measurements of O2 saturation, pulse rate, respiration and pulse and breathe distension. (c) Profile of arterial O2 saturation measurement in rat during MRI acquisitions at 100% and 21% O2 during inhalation anaesthesia with isoflurane.
Figure 6Several systems available for monitoring blood pressure. They include Millar probes (Millar Mikro-Tip®, Millar Sensors Systems, ADInstruments Ltd., Oxford, UK), fibre optic transducer, (which are most suitable for MRI imaging (e.g. Samba Preclin catheter®; Samba Sensors AB, Västra Frölunda, Sweden) and pressure transducers (TSD104A blood pressure transducer; Biopac Systems, Inc., Goleta, CA, USA). The perivascular flow probes (Transonic Systems, Inc., Ithaca, NY, USA) provide good precision blood pressure measurements for small animal vessels (0.25 mm) without the need to expose the lumen of the vessels, although the procedure still requires surgical exposure of the vessels to localise and fix the transducer around the vessel wall [64]. Indirect blood pressure method (non-invasive) involves inflating a cuff around the tail which works as a pressure transducer measuring the blood flow in the tail artery.